AF
Finckh, Axel
Affiliation entities
Research groups
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Rhumatismes inflammatoires : où en est-on avec les JAK-inhibiteurs ? | Rheuma Plus / Schweiz | 2025 | 6 | 33 | |||
| Identification of individuals at high risk of developing rheumatoid arthritis : a balanced random forest model in a cohort of 1544 first-degree relatives | RMD open | 2025 | 7 | 22 | |||
| Reply | Arthritis & rheumatology | 2025 | 8 | 0 | |||
| Antibiotics in inflammatory arthritis and background population one year before and after diagnosis : a nationwide drug utilization study | Rheumatology | 2025 | 5 | 0 | |||
| When borders impact science : what is the future of European rheumatology research ? | Annals of the rheumatic diseases | 2025 | 4 | 0 | |||
| Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs : data from an international collaboration of registries (the "JAK-pot" study) | Arthritis & rheumatology | 2025 | 79 | 49 | |||
| Antirheumatic drugs in reproduction, pregnancy, and lactation : a systematic literature review informing the 2024 update of the EULAR recommendations | Annals of the rheumatic diseases | 2025 | 17 | 280 | |||
| The epidemiology of RA | Nature reviews. Rheumatology | 2025 | 5 | 0 | |||
| Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | 2025 | 45 | 0 | |||
| Rhumatologie : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 50 | 30 | |||
| Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index : a cohort study in a Swiss registry | BMJ open | 2024 | 8 | 14 | |||
| Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis : the ROC-SpA study, a randomised controlled study protocol | BMJ open | 2024 | 6 | 19 | |||
| Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox inrheumatoid arthritis | ESC (Europan Society of Cardiology) Congress 2024 | 2024 | 4 | 0 | |||
| Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis | RMD open | 2024 | 105 | 63 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 7 | 0 | |||
| Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study) | Annals of the rheumatic diseases | 2024 | 94 | 73 | |||
| Explainable deep learning for disease activity prediction in chronic inflammatory joint diseases | PLOS digital health | 2024 | 6 | 10 | |||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | 2024 | 114 | 150 | |||
| Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA | BMJ open | 2024 | 134 | 95 | |||
| Tofacitinib Monotherapy in Rheumatoid Arthritis : Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention | Open access rheumatology | 2024 | 7 | 9 | |||
| Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | 2024 | 100 | 92 | |||
| 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer | Annals of the rheumatic diseases | 2024 | 56 | 430 | |||
| Concomitant Sjögren's disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort | Arthritis research & therapy | 2024 | 5 | 8 | |||
| Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study | Frontiers in medicine | 2023 | 67 | 83 | |||
| Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab | RMD open | 2023 | 83 | 29 | |||
| The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: predicting clinical arthritis development | Scandinavian journal of rheumatology | 2023 | 145 | 130 | |||
| A potential role for chlamydial infection in rheumatoid arthritis development | Rheumatology | 2023 | 91 | 166 | |||
| Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy | Rheumatology | 2023 | 79 | 134 | |||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the rheumatic diseases | 2023 | 255 | 230 | |||
| Characterization of serum biomarkers and antibody responses against Prevotella spp. in preclinical and new-onset phase of rheumatic diseases | Frontiers in cellular and infection microbiology | 2023 | 109 | 82 | |||
| Brief report : assessment of mucosal barrier integrity using serological biomarkers in preclinical stages of rheumatoid arthritis | Frontiers in immunology | 2023 | 184 | 211 | |||
| Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries | Arthritis research & therapy | 2023 | 67 | 137 | |||
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | 2023 | 130 | 81 | |||
| Management of giant-cell arteritis in Switzerland: an online national survey | Swiss medical weekly | 2023 | 230 | 230 | |||
| Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumab | JAMA neurology | 2022 | 244 | 160 | |||
| EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology | Annals of the rheumatic diseases | 2022 | 209 | 75 | |||
| After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries | Annals of the rheumatic diseases | 2022 | 265 | 412 | |||
| Nouveautés en médecine 2021 - Rhumatologie | Revue médicale suisse | 2022 | 295 | 205 | |||
| Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study | Annals of the rheumatic diseases | 2022 | 292 | 112 | |||
| Periodontitis in first degree-relatives of individuals with rheumatoid arthritis: a short narrative review | Frontiers in oral health | 2022 | 202 | 85 | |||
| Prévention vaccinale chez les patients avec des maladies rhumatismales | Revue médicale suisse | 2022 | 110 | 104 | |||
| Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort | PloS one | 2022 | 70 | 44 | |||
| Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions | Statistical methods in medical research | 2022 | 146 | 107 | |||
| Global epidemiology of rheumatoid arthritis | Nature reviews. Rheumatology | 2022 | 354 | 1 | |||
| Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study | Clinical infectious diseases | 2022 | 232 | 53 | |||
| Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration | Annals of the rheumatic diseases | 2022 | 337 | 96 | |||
| Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases | Frontiers in immunology | 2022 | 203 | 76 | |||
| Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : a descriptive cohort study assessing trends in patient characteristics in Switzerland | BMJ open | 2022 | 61 | 49 | |||
| Editoria : The interplay between the oral microbiota and rheumatoid arthritis | Frontiers in oral health | 2022 | 108 | 68 | |||
| Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis | Rheumatology | 2021 | 378 | 451 | |||
| EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors | Annals of the Rheumatic Diseases | 2021 | 250 | 719 | |||
| Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis | BMJ Open | 2021 | 354 | 154 | |||
| Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients | Rheumatology advances in practice | 2021 | 160 | 89 | |||
| Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in Switzerland | Journal of Clinical Medicine | 2021 | 222 | 113 | |||
| Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profiling | International Journal of Immunogenetics | 2021 | 215 | 0 | |||
| Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology | RMD open | 2021 | 262 | 143 | |||
| Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort | Annals of the Rheumatic Diseases | 2021 | 185 | 227 | |||
| Greater trochanteric pain syndrome: predicting who will respond to a local glucocorticoid injection | Scandinavian Journal of Rheumatology | 2021 | 255 | 0 | |||
| Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis | Rheumatology | 2021 | 262 | 0 | |||
| Primary and secondary non-response: in need of operational definitions in observational studies | Annals of the Rheumatic Diseases | 2021 | 252 | 84 | |||
| Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries | Annals of the Rheumatic Diseases | 2021 | 207 | 282 | |||
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | 2021 | 243 | 0 | |||
| Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literature | Thérapie | 2021 | 1,166 | 1 | |||
| Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trial | BMJ open | 2021 | 250 | 143 | |||
| Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction | RMD Open | 2021 | 259 | 69 | |||
| Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab | RMD open | 2021 | 261 | 105 | |||
| Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network | PLOS ONE | 2021 | 294 | 185 | |||
| EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis | Annals of the Rheumatic Diseases | 2021 | 373 | 107 | |||
| Is the prevention of rheumatoid arthritis possible? | Clinical Rheumatology | 2020 | 177 | 0 | |||
| Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis | Arthritis Research and Therapy | 2020 | 413 | 333 | |||
| EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases | Annals of the Rheumatic Diseases | 2020 | 350 | 0 | |||
| Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study | The Lancet. Rheumatology | 2020 | 244 | 219 | |||
| smarter medicine: liste Top-5 pour le traitement des rhumatismes | Bulletin des médecins suisses | 2020 | 118 | 66 | |||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases | 2020 | 484 | 291 | |||
| Measuring ACPA in the general population or primary care: is it useful? | RMD Open | 2020 | 239 | 172 | |||
| Mini-Review: Human Microbiome and Rheumatic Diseases | Frontiers in cellular and infection microbiology | 2020 | 193 | 179 | |||
| Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making | Clinical Rheumatology | 2020 | 205 | 0 | |||
| Predictive factors of treatment persistence in rheumatoid arthritis | Joint, Bone, Spine | 2020 | 422 | 634 | |||
| Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland | RMD Open | 2020 | 217 | 97 | |||
| Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life | Joint, Bone, Spine | 2020 | 359 | 0 | |||
| The role of nutritional factors and intestinal microbiota in rheumatoid arthritis development | Nutrients | 2020 | 169 | 179 | |||
| Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease | Rheumatology | 2020 | 324 | 8 | |||
| Periodontal status correlates with anti‐citrullinated protein antibodies in first‐degree relatives of individuals with rheumatoid arthritis | Journal of Clinical Periodontology | 2019 | 423 | 2 | |||
| Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis | Clinical and Experimental Rheumatology | 2019 | 383 | 187 | |||
| Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | 2019 | 371 | 0 | |||
| EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases | RMD Open | 2019 | 335 | 190 | |||
| Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? | RMD Open | 2019 | 334 | 147 | |||
| Menopause and possible effect on association between age and anticyclic citrullinated peptide antibodies in women at risk of rheumatoid arthritis | Journal of Rheumatology | 2019 | 301 | 0 | |||
| Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years | Rheumatology | 2019 | 308 | 174 | |||
| Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trial | Clinical Rheumatology | 2019 | 315 | 0 | |||
| The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis | British Journal of Haematology | 2019 | 258 | 0 | |||
| Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort | Rheumatology | 2019 | 270 | 0 | |||
| 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis | Annals of the Rheumatic Diseases | 2019 | 344 | 262 | |||
| Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric | Quality of Life Research | 2019 | 272 | 145 | |||
| Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries | Annals of the Rheumatic Diseases | 2019 | 364 | 0 | |||
| Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis | RMD Open | 2019 | 337 | 101 | |||
| Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individuals | PLOS ONE | 2019 | 307 | 238 | |||
| Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations | RMD Open | 2019 | 342 | 137 | |||
| Prevotella copri in individuals at risk for rheumatoid arthritis | Annals of the Rheumatic Diseases | 2019 | 466 | 0 | |||
| Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis | Clinical Therapeutics | 2019 | 293 | 1 | |||
| Intestinal dysbiosis in RA development: difficulty of establishing causality. Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Inamo | Annals of the Rheumatic Diseases | 2019 | 340 | 4 | |||
| Lessons learned from rheumatoid arthritis registries | Joint, Bone, Spine | 2018 | 444 | 3 | |||
| Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project | RMD Open | 2018 | 462 | 194 | |||
| Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider | RMD Open | 2018 | 319 | 224 | |||
| EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology | RMD Open | 2018 | 319 | 206 | |||
| Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort | Journal of Rheumatology | 2018 | 460 | 1 | |||
| Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis | Medical Decision Making | 2018 | 474 | 0 | |||
| 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis | Annals of the Rheumatic Diseases | 2018 | 427 | 0 | |||
| Microbiotes et rhumatismes inflammatoires | Revue médicale suisse | 2018 | 499 | 158 | |||
| Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland | Memórias do Instituto Oswaldo Cruz | 2018 | 599 | 213 | |||
| Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial | Arthritis Care and Research | 2018 | 366 | 1 | |||
| Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | 2018 | 435 | 433 | |||
| Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis | Rheumatology | 2017 | 550 | 5 | |||
| Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers | Annals of the Rheumatic Diseases | 2017 | 500 | 241 | |||
| Value of Biomarkers in the Prevention of Rheumatoid Arthritis | Clinical Pharmacology and Therapeutics | 2017 | 456 | 0 | |||
| The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | 2017 | 629 | 3 | |||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | 2017 | 482 | 2 | |||
| Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM) | Clinical Rheumatology | 2017 | 406 | 0 | |||
| Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype | PloS one | 2017 | 559 | 304 | |||
| Environmental factors and hormones in the development of rheumatoid arthritis | Seminars in Immunopathology | 2017 | 480 | 0 | |||
| Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA) | Clinical Rheumatology | 2017 | 481 | 2 | |||
| The role of female hormonal factors in the development of rheumatoid arthritis | Rheumatology | 2017 | 467 | 0 | |||
| Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life | Quality of life research | 2017 | 524 | 1 | |||
| New viral outbreaks: time for rheumatologists to get involved? | Rheumatology | 2017 | 462 | 0 | |||
| Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis | Annals of the rheumatic diseases | 2016 | 593 | 0 | |||
| The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis | Arthritis & rheumatology | 2016 | 527 | 0 | |||
| Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative | Annals of the Rheumatic Diseases | 2016 | 456 | 0 | |||
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | 2016 | 932 | 275 | |||
| Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study | Joint, Bone, Spine | 2016 | 535 | 0 | |||
| Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences | Current rheumatology reports | 2016 | 561 | 1 | |||
| Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis | Arthritis and Rheumatology | 2016 | 381 | 0 | |||
| Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study | EBioMedicine | 2016 | 485 | 204 | |||
| Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis | Journal of managed care & specialty pharmacy | 2015 | 588 | 0 | |||
| Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | Rheumatology | 2015 | 499 | 0 | |||
| The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers | Rheumatology | 2015 | 599 | 291 | |||
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | 2015 | 705 | 0 | |||
| The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis | Clinical rheumatology | 2015 | 566 | 0 | |||
| An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks | Clinical rheumatology | 2015 | 472 | 0 | |||
| Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria | Rheumatology international | 2015 | 599 | 0 | |||
| Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study | Annals of the rheumatic diseases | 2015 | 645 | 0 | |||
| Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study | Annals of the rheumatic diseases | 2015 | 569 | 323 | |||
| The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries | RMD open | 2015 | 481 | 248 | |||
| Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study | Inflammatory bowel diseases | 2015 | 492 | 0 | |||
| The impact of obesity on the development and progression of rheumatoid arthritis | Annals of the rheumatic diseases | 2014 | 561 | 0 | |||
| Immune-mediated experimental arthritis in IL-33 deficient mice | Cytokine | 2014 | 675 | 0 | |||
| Prevention of rheumatic diseases: strategies, caveats, and future directions | Rheumatic diseases clinics of North America | 2014 | 492 | 0 | |||
| Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee | International orthopaedics | 2014 | 579 | 0 | |||
| Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK | PharmacoEconomics | 2014 | 525 | 501 | |||
| Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs? | Journal of rheumatology | 2014 | 525 | 0 | |||
| Facteurs de risque pour le développement d'une polyarthrite rhumatoïde | Revue médicale suisse | 2014 | 532 | 2 | |||
| Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study | Annals of the rheumatic diseases | 2014 | 616 | 605 | |||
| Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort study | Joint bone spine | 2014 | 593 | 0 | |||
| Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial | Arthritis research & therapy | 2014 | 706 | 229 | |||
| Complications cardio-vasculaires dans les maladies auto-immunes | Revue médicale suisse | 2013 | 547 | 1 | |||
| Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry | Joint bone spine | 2013 | 559 | 0 | |||
| Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency | Arthritis research & therapy | 2013 | 645 | 282 | |||
| Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population | Joint bone spine | 2013 | 626 | 1 | |||
| Do synovial leptin levels correlate with pain in end stage arthritis? | International orthopaedics | 2013 | 674 | 208 | |||
| Smoking and spondyloarthritis | Joint bone spine | 2013 | 562 | 1 | |||
| The importance of early treatment for the prognosis of rheumatoid arthritis | Schweizerische medizinische Wochenschrift | 2013 | 656 | 306 | |||
| Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial | Annals of the rheumatic diseases | 2012 | 672 | 0 | |||
| Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists | Annals of the rheumatic diseases | 2012 | 564 | 428 | |||
| Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? | Arthritis care & research | 2012 | 695 | 0 | |||
| Pain as an important predictor of psychosocial health in patients with rheumatoid arthritis | Arthritis care & research | 2012 | 661 | 0 | |||
| EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis | Annals of the rheumatic diseases | 2012 | 700 | 570 | |||
| Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients | Annals of the rheumatic diseases | 2012 | 678 | 0 | |||
| Spontaneous secretion of interleukin-17 and -22 by human cervical cells in Chlamydia trachomatis infection | Microbes and infection | 2011 | 617 | 0 | |||
| Patient repositioning reproducibility of joint space with (JSW) measurements on hand radiographs | Arthritis care & research | 2011 | 483 | 0 | |||
| Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center | Arthritis and rheumatism | 2011 | 686 | 0 | |||
| The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study | Rheumatology | 2011 | 607 | 0 | |||
| Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis | Arthritis and rheumatism | 2011 | 645 | 0 | |||
| Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion | Rheumatology | 2011 | 510 | 0 | |||
| Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis | Annals of the rheumatic diseases | 2011 | 588 | 0 | |||
| EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology | Annals of the rheumatic diseases | 2010 | 591 | 0 | |||
| Osteoarthritis: Small studies overestimate the benefit of therapies for OA | Nature reviews. Rheumatology | 2010 | 688 | 0 | |||
| Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients | Joint bone spine | 2010 | 618 | 0 | |||
| Diagnostic value of anti-cyclic citrullinated peptides and association with HLA-DRB1 shared epitope alleles in African rheumatoid arthritis patients | Arthritis research & therapy | 2010 | 788 | 554 | |||
| Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis | Arthritis and rheumatism | 2010 | 903 | 3 | |||
| Cost-effectiveness of biologics in early rheumatoid arthritis | Annals of internal medicine | 2010 | 523 | 0 | |||
| The effect of alcohol on radiographic progression in rheumatoid arthritis | Arthritis and rheumatism | 2010 | 596 | 0 | |||
| Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? | Annals of the rheumatic diseases | 2010 | 595 | 0 | |||
| Comparative effectiveness of rheumatoid arthritis therapies | Current rheumatology reports | 2010 | 523 | 0 | |||
| Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis | Schweizerische medizinische Wochenschrift | 2010 | 569 | 0 | |||
| A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries | Seminars in arthritis and rheumatism | 2010 | 632 | 0 | |||
| Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial | Arthritis and rheumatism | 2010 | 674 | 0 | |||
| Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis | Arthritis and rheumatism | 2009 | 658 | 0 | |||
| Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies | Schweizerische medizinische Wochenschrift | 2009 | 632 | 333 | |||
| Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis | Arthritis and rheumatism | 2009 | 627 | 0 | |||
| BMI and severity of clinical and radiographic signs of hip osteoarthritis | Obesity | 2009 | 988 | 0 | |||
| Influence of cytokine inhibitors on concentration and activity of MMP-1 and MMP-3 in disc herniation | Arthritis research & therapy | 2009 | 664 | 241 | |||
| The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study | Annals of the rheumatic diseases | 2009 | 610 | 0 | |||
| Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc | Spine | 2008 | 678 | 0 | |||
| At the horizon of innovative therapy in rheumatology: new biologic agents | Current opinion in rheumatology | 2008 | 629 | 0 | |||
| Primer: strengths and weaknesses of meta-analysis | Nature clinical practice rheumatology | 2008 | 670 | 0 | |||
| Neutral functional realignment orthosis prevents hand pain in patients with subacute stroke: a randomized trial | Archives of physical medicine and rehabilitation | 2008 | 603 | 0 | |||
| B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents | Arthritis and rheumatism | 2007 | 178 | 1 | |||
| Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women | Arthritis and rheumatism | 2006 | 243 | 501 | |||
| Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management | Annals of the rheumatic diseases | 2004 | 508 | 2 | |||
| Neurophysiologic evidence for a central sensitization in patients with fibromyalgia | Arthritis and rheumatism | 2003 | 544 | 850 |
